Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...
Bottle Raiders on MSN8h
Japan Spirits Association Unveils Logo to Be Found on Bottles of Authentic Japanese WhiskyThe Japan Spirits & Liqueurs Makers Association announced on Thursday the introduction of a new logo to help consumers identify whiskies that meet its industry standards. The association hopes this ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...
South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target of €100.00. The company’s shares closed ...
March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...
After sitting on ice for most of the winter, the Corporate Transparency Act (CTA) is ready to spring into action. Companies must comply with the law’s reporting requirements by March 21 ...
The Treasury Department announced it would no longer enforce the Corporate Transparency Act, nor enforce any penalties or fines associated with beneficial ownership reporting under the existing ...
Results from those studies in 2019 enabled the Sanofi and Regeneron antibody to become the first treatment approved by the FDA in inadequately controlled CRSwNP. Dupixent’s 52-week placebo ...
Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...
Ewan Palmer is a Newsweek News Reporter based in London, U.K. His focus is reporting on US politics, and Florida news. He joined Newsweek in February 2018 after spending several years working at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback